UNSPSC 51191805: Potassium citrate

This classification denotes an electrolyte replacement agent with the molecular formula C6H5O7.3K.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EE90ONI6FF, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, tripotassium salt but more generally known as potassium citrate, which bears U.S. NIH Compound Identifier 13344. European Medicines Agency schedules Potassium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14973MIG.

World Health Organization schedules potassium citrate in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51191805 Potassium citrate is a Commodity code under which state and local governments procure chemical products for water treatment, facility maintenance, and pharmaceutical supply operations. Recent opportunities show municipal water pollution control facilities and multistate cooperative purchasing alliances buying specialized chemicals and pharmaceutical products through competitive bid and RFP processes, with scope spanning both direct chemical supply for treatment systems and aggregated pharmaceutical and OTC product distribution networks serving multiple public-sector facilities across state lines.

The issuing-body mix includes municipal water departments (City of Meriden, Connecticut) and state-administered cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating member jurisdictions). Geographic activity appears concentrated in Connecticut and the Upper Midwest, with the MMCAP cooperative extending procurement across multiple states through authorized wholesalers. Representative recent opportunities include the City of Meriden's IFB for sodium bisulfite chemical supply for its Water Pollution Control Facility (solicitation B027-15, due July 29, 2026), requiring General Liability coverage of $1,000,000 to $2,000,000 and performance and payment bonds; and the Minnesota Department of Administration's RFP through MMCAP to establish multiple contracts for generic pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026), which aggregates procurement across state and local government facilities with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and 3 percent administrative fee acceptance.